Winncare Group has acquired Mangar Health
December 2018 — Winncare Group, a medical equipment manufacturer, has acquired Mangar Health, an inflatable lifting and bathing device manufacturer and supplier. Financial details have not been disclosed.
Winncare is a medical device producer specialized in the design, manufacturing and supply of medical equipment and services for dependent and elderly people. The company's products include mattresses addressing all types of pressure sore risks, cushions and positioning accessories for the prevention and treatment of pressure sores, medical beds and other medical equipment such as lifts, trolleys and handicap management products. The group manufactures its products in five facilities in France, Spain, Nordic countries, Poland and Tunisia. Winncare benefits from a strong R&D team collaborating with top-ranking medical research institutions, allowing the company to offer a unique medical value proposition to patients and medical staff.
The acquisition of Mangar Health will now see Winncare continue its European growth ambitions, providing the ability to service new healthcare markets such as emergency services, whilst also benefiting from the British manufacturer’s international distribution network in America, Canada and Australia. Additionally, the purchase will allow Winncare to fast-track entry into UK markets where Mangar has established relationships with care providers, local authorities, ambulance services and care homes.
Mangar Health designs, manufactures and supplies inflatable bathing and lifting devices, which protect carers from injury and promote independence for people with limited mobility. With a global reach into America, Canada and Australia, Mangar Health also offers a wide international distribution network and additional opportunities in healthcare markets such as emergency services.
Our role in the transaction
Oaklins’ team in France advised Winncare and IDI in the design and execution of their external growth strategy. With the help of Oaklins’ teams around the world, more that 50 targets were identified. Oaklins Smith & Williamson, based in the UK, introduced Mangar Health.
Talk to the deal team
Related deals
Comtax has been acquired by Ryan
Comtax, a São Paulo-based tax technology consultancy specializing in tax determination and digital tax compliance, had been acquired by Ryan, the world’s largest firm dedicated exclusively to business taxes. The transaction marks Ryan’s entry into the Brazilian market, adding a specialized team and an established base of large corporate clients in Brazil, one of the world’s most complex tax environments, at a time when the country’s consumption tax reform is set to reshape how companies calculate and report indirect taxes. For Comtax, the acquisition brings access to Ryan’s global platform, technology and client network across more than 80 countries, creating opportunities to scale its tax determination and compliance offering beyond its current footprint. Comtax’s founders will continue to lead the business.
Learn moreCibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more